Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

This study found that low-output laser irradiation demonstrates biostimulatory effects on several biological systems and processes, including hair growth, wound healing, and immune function, with effects influenced by dose and exhibiting both stimulatory and inhibitory potential.

This study found that the oral Janus kinase inhibitor CP-690,550 has a direct effect on reducing pruritus in patients with psoriasis, independent of clinician-assessed improvements in psoriasis severity.

This study found that deficiency in TLR3/TRIF signaling reduced inflammation and protected mice against postoperative ileus, suggesting potential for TLR3 antagonism as a preventive approach in humans.

This study found that in patients with alopecia areata, platelet-rich plasma therapy reduced elevated levels of interleukin-17A and interleukin-2 to control levels after 17 months.

In this study, intralesional triamcinolone acetonide was found to be more effective than platelet rich plasma and placebo for moderate to severe alopecia areata, but had a higher relapse rate.

This study found that innate lymphoid cells-type 1 (ILC1) can induce alopecia areata by disrupting hair follicle immune privilege without the involvement of classical CD8+ T cells.

This review synthesizes cases of biopsy-confirmed alopecia areata occurring in patients using IL-17 or IL-23 inhibitors, suggesting the need for increased awareness and further investigation into this rare adverse event.

In this study, researchers evaluated CS12192, a selective JAK3 inhibitor, in an alopecia areata mouse model and found it reversed hair growth inhibition comparably to baricitinib, with better safety and similar immune-modulating mechanisms.

This study suggests that IL-1β may play a role in inflammatory signaling pathways in papulopustular rosacea, contributing to its pathogenesis.

Ixekizumab effectively treats generalized pustular psoriasis.

In this study, a patient with clinically amyopathic dermatomyositis experienced persistent skin issues despite treatment, highlighting questions about type I interferon's role in skin disorders and potential IFN-targeted therapies for cutaneous lupus erythematosus and dermatomyositis.

In this case report, two patients with polyautoimmunity and difficult-to-treat lupus erythematosus experienced significant symptom improvement after adding anifrolumab to their regimen, suggesting its potential as an effective add-on therapy for refractory cutaneous symptoms in autoimmune conditions characterized by elevated interferon alpha activity.

This study found that IL-17 expression was significantly higher in perifollicular fibrosis of active Lichen planopilaris lesions, suggesting that targeting IL-17 could impact the disease's progression.

In this preclinical study, researchers developed and evaluated a new non-invasive laser system designed for personalized medical use, showing its potential for chronic disease management and adjunctive fat reduction by offering enhanced treatment precision and adaptability over existing devices.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.

In this study, researchers investigated the role of the ATX-LPA axis in asthma pathogenesis using human and mouse models and highlighted the potential for developing new ATX inhibitors as effective asthma treatments.

This case report describes a 62-year-old male with multiple warty dyskeratomas found on the scalp, chest, abdomen, and lower back, a rare presentation confirmed by histological findings consistent with warty dyskeratoma, as noted by the researchers.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

This study found that in individuals with alopecia areata, intralesional Triamcinolone therapy led to significantly greater reduction in disease severity, measured by SALT scores, compared to autologous platelet-rich plasma treatment over a 24-week period.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

In this study, ustekinumab did not promote hair regrowth in human patients with alopecia areata or prevent disease development in an AA mouse model, suggesting limited efficacy for this treatment.

In this case report, the authors concluded that cutaneous lupus erythematosus was induced by the PD-1 inhibitor tislelizumab during treatment for metastatic lung adenocarcinoma, despite initial remission and treatment adjustments.

This study demonstrated that a 1-step, peroxidase-labeled conjugated antibody method provides more accurate immunoreactivity patterns in hair follicle substructures compared to the 2-step LSAB method, which may cause false-positive staining in sebaceous glands.

This case report by the researchers observed a complete remission of lichen planopilaris in a 58-year-old woman after treatment with the JAK-1 inhibitor abrocitinib, although they noted that concurrent topical therapy might have contributed to this outcome.

Laser treatment for skin conditions VEN and ILVEN is effective and liked by patients.